Trial Profile
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary) ; Nivolumab (Primary) ; Anti-CTLA-4 monoclonal antibody
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CORE2; NAOMI
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 01 Mar 2023 Planned End Date changed from 1 Nov 2023 to 1 Mar 2025.
- 01 Mar 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Mar 2025.